Myelodysplastic syndromes trials in Germany

In Germany 28 Also abroad 369

28 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Berlin, Munich, Ulm
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Where
Berlin, Bonn, Duesseldorf, Halle (Saale), Leipzig, Magdeburg
Age
18 years and over
People
225 worldwide
Run by
Takeda
See details and how to joinNCT06499285 · EU 2024-516009-22-00
Phase 3Taking people
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Where
Bayreuth, Berlin, Halle (Saale), Muenster
Age
18 years and over
People
300 worldwide
Run by
Takeda
See details and how to joinNCT07422480 · EU 2025-523544-12-00
No phaseTaking people
First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms
Where
Mainz
Age
18 years and over
People
190
Run by
Bristol-Myers Squibb
See details and how to joinNCT07752121
Phase 3Taking people
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Where
Arnsberg, Aschaffenburg, Bad Saarow, Berlin, Bochum, Bonn, Bremen, Brunswick, Darmstadt, Dortmund, Frankfurt Am Main, Giessen, Goch, Greifswald, Halle (Saale), Hamburg, Hamm, Hannover, Hanover, Heilbronn, Herne, Homburg, Kaiserslautern, Karlsruhe, Lübeck, Ludwigshafen Am Rhein, Magdeburg, Mainz, Minden, Munich, Offenburg, Oldenburg, Regensburg, Rostock, Stuttgart, Traunstein, Trier, Tuebingen, Ulm, Villingen-Schwenningen, Wuppertal
Age
18 years to 75 years
People
650 worldwide
Run by
University of Ulm
See details and how to joinNCT04628026 · EU 2023-507518-28-00
Phase 1/2Taking people
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Where
Dresden, Frankfurt Am Main, Halle (Saale), Heidelberg, Munich, Ulm
Age
16 years and over
People
85 worldwide
Run by
AstraZeneca
See details and how to joinNCT07155226 · EU 2025-521299-76-00
Phase 2Taking people
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Where
Bayreuth, Berlin, Bonn, Duesseldorf, Esslingen am Neckar, Halle (Saale), Mainz
Age
18 years and over
People
210 worldwide
Run by
Takeda
See details and how to joinNCT04419649 · EU 2023-507469-24-00
Phase 1/2Taking people
AZALOX Study: Safety and Efficacy of PXS-5505 with 5-Azacitidine in MDS and CMML Patients
Where
Bonn, Dresden, Duesseldorf, Goettingen, Hanover, Luebeck, Mainz, Mannheim, Munich, Oldenburg
Age
18 years and over
People
42
Run by
Heidelberg University
See details and how to join2024-517237-40-00 · EU 2024-517237-40-00
Phase 2Taking people
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Where
Dresden, Düsseldorf, Hamburg, Lübeck, Munich, Tübingen
Age
18 years and over
People
156 worldwide
Run by
Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00
Phase 3Taking people
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Where
Berlin, Dresden, Duesseldorf, Halle (Saale), Leipzig, Stuttgart, Ulm
Age
18 years and over
People
490 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00
Phase 2/3Taking people
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Where
Brunswick, Freiburg im Breisgau, Halle Saale, Heidelberg
Age
18 years and over
People
316 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00
Phase 4Taking people
Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.
Where
Augsburg, Berlin, Bochum, Brunswick, Chemnitz, Cologne, Dresden, Erfurt, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Hanover, Herne, Jena, Kiel, Leipzig, Magdeburg, Muenster, Munich, Regensburg, Rostock, Tuebingen, Ulm
Age
18 years and over
People
365 worldwide
Run by
Medizinische Hochschule Hannover
See details and how to join2024-512503-39-00 · EU 2024-512503-39-00
Phase 1/2Taking people
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Where
Aachen, Cologne, Duesseldorf, Frankfurt Am Main, Jena, Munich
Age
18 years and over
People
38
Run by
Heinrich-Heine University, Duesseldorf
See details and how to joinNCT05807932 · EU 2024-514688-24-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Aachen, Freiburg im Breisgau, Lübeck, Mannheim
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Leipzig, Ulm
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 3Taking people
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Where
Dresden, Duesseldorf, Goettingen, Hanover, Leipzig, Munich
Age
18 years and over
People
48 worldwide
Run by
Institut de Recherches Internationales Servier
See details and how to joinNCT06465953 · EU 2023-510155-37-00
Phase 2Taking people
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
Where
Aachen, Augsburg, Berlin, Chemnitz, Cologne, Dresden, Frankfurt am Main, Greifswald, Halle, Jena, Kiel, Leipzig, Mainz, Münster, Nuremberg, Rostock, Stuttgart
Age
18 years and over
People
220
Run by
Technische Universität Dresden
See details and how to joinNCT07025824
No phaseNot yet taking people in Germany
Dresden MDS Registry With an Accompanying Biomaterial Collection
Where
Dresden
Age
18 years and over
People
500
Run by
Technische Universität Dresden
See details and how to joinNCT07561385
Phase 2Taking people
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
Where
Aachen, Chemnitz, Dresden, Erlangen, Essen, Frankfurt Am Main, Greifswald, Halle (Saale), Hamburg, Jena, Kiel, Leipzig, Mainz, Mannheim, Muenster, Munich, Oldenburg, Rostock, Ulm
Age
18 years to 75 years
People
76
Run by
Technische Universität Dresden
See details and how to joinNCT06717958 · EU 2023-509055-14-00
Phase 2Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Where
Brunswick, Luebeck
Age
18 years and over
People
332 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01
Phase 1/2Not yet taking people in Germany
A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies
Where
Berlin, Dresden, Heidelberg, Jena, Leipzig, Munich, Ulm
Age
18 years and over
People
64 worldwide
Run by
Servier
See details and how to joinNCT07719348 · EU 2025-525128-88-00
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Berlin, Dresden, Düsseldorf, Halle, Hamburg, Hanover, Leipzig, Mainz, München
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 2Taking people
A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Where
Dresden, Leipzig, Luebeck, Mainz, Muenster, Munich
Age
18 years and over
People
80 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06847867 · EU 2024-519928-24-00
No phaseTaking people
Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
Where
Freiburg im Breisgau
Age
Up to 17 years
People
260
Run by
University Hospital Freiburg
See details and how to joinNCT00662090
Phase 2Not yet taking people in Germany
Venetoclax- Augmented Treosulfan-Based Reduced Intensity Conditioning Before Allogeneic Stem Cell Transplantation
Where
Tuebingen
Age
18 years to 75 years
People
27
Run by
University Hospital Tuebingen
See details and how to joinNCT07214064 · EU 2025-521372-62-00